Replimune股东诉讼提醒重复扩散，核心FDA拒信与股价下跌事实已在4月和8月多次披露

Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial designs the FDA had already questioned, including response criteria the agency said were not consistent with RECIST v1.1.
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of Replimune Group, Inc. (NASDAQ: REPL) securities of a pending securities class action brought on behalf of investors who acquired shares between October 20, 2025 and April 10, 2026. Find out if you might qualify for recovery. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
REPL closed at a Class Period high of $10.73 on December 8, 2025. Shares fell $1.15 (19.46%) to $4.76 on April 10, 2026, then $3.06 (64.29%) to $1.70 on April 13, 2026, a cumulative decline of roughly $9.03 per share, or 84.16%. Motions for lead plaintiff must be filed with the Court by October 5, 2026.
The Alleged Clinical Trial Design Deficiency
RP1 was studied in RPL-001-16 (IGNYTE) in combination with Bristol Myers Squibb's nivolumab. As pleaded, that trial was single-arm and was not designed to isolate what RP1 itself contributed to the observed response rate. Plaintiffs allege that this design limitation, and the FDA's previously communicated concerns about it, were not disclosed to shareholders while the Company described the resubmission as a complete response to the July 2025 complete response letter.
Regulatory Strategy and Response Criteria
The action contends that the FDA had recommended using data from the ongoing Phase 3 program to potentially support accelerated approval, and had flagged that the response criteria applied in RPL-001-16 were not consistent with RECIST v1.1 and might not be comparable to historical literature. Instead, an early unplanned analysis from RP1-104 covering 40 patients, about 10% of the planned 400-patient enrollment, was submitted.
Operational Gaps Alleged in the RP1 Program
- Trial design that allegedly could not separate RP1's effect from nivolumab's
- Alleged failure to adopt the randomized controlled trial the agency preferred
- Response assessment allegedly inconsistent with RECIST v1.1 standards
- Reliance on an early unplanned interim analysis rather than planned Phase 3 data
- Study design concerns the FDA stated were "clearly communicated" but allegedly unaddressed
- Disclosure that without approval the Company might be required to restructure and reprioritize the RPx portfolio
"The complaint raises serious questions about whether shareholders received accurate information about the sufficiency of the RP1 trial designs that regulators had already scrutinized. Investors are entitled to evaluate that record for themselves." -- Joseph E. Levi, Esq.
Submit your information now or call (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the REPL Lawsuit
Q: Who is eligible to join the REPL investor lawsuit? A: Investors who purchased REPL stock or securities between October 20, 2025 and April 10, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What court was the REPL class action filed in? A: The case was filed in the United States District Court for the District of Massachusetts, governed by the Private Securities Litigation Reform Act of 1995.
Q: Who are the defendants named in the REPL lawsuit? A: The complaint names Replimune Group, Inc. and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.
Q: What do REPL investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. No immediate action is required to remain eligible as an absent class member.
Q: What documents do I need to to submit my information? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my REPL shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if Replimune Group, Inc. goes bankrupt before the case resolves? A: Securities class action claims may survive bankruptcy in many circumstances. D&O insurance policies are frequently a potential source of settlement funds.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
Tel: (888) SueWallSt\
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE SueWallSt.com